Two dosages (5 mg and 25 mg) of the selective 5HT3 receptor antagonist tropisetron (lCS 205-930) were administered to healthy male controls, and the effects on the sleep EEG and nocturnal secretory activity of growth hormone (GH) and cortisol were evaluated. The lower dosage was administered to four subjects and the higher dosage to eight on 5 consecutive days, preceded and followed by 2 days of placebo treatment. After 25 mg of tropisetron, there was a slight increase in REM sleep in the first part of the sleep period, and stage 2 was decreased during the total night. In addition, plasma cortisol levels increased earlier than under placebo, and plasma GH levels were reduced in the second part of the night. Thus, only discrete effects of tropisetron upon sleep-endocrine activity were noted, making it unlikely that serotoninergic neurotransmission exerts its well documented effects upon sleep through 5HT3 receptors.
Research in animals and humans indicates that sero toninergic and catecholarninergic neurotransmission play an important role in regulating behavior, spe cifIcally waking and sleep. Early work by Jouvet (1967 Jouvet ( , 1972 suggested that serotoninergic neurons of brain stem raphe nuclei are responsible for inducing slow wave sleep, and that pontomesencephalic catechol ami ne-containing neurons are implicated in rapid eye movement (REM) sleep and in the maintenance of wakefulness. Although this hypothesis had an enor mous heuristic impact, subsequent research revealed that central processes regulating sleep are much more complex (Koella 1985; Puizillout et a1. 1981; Cespuglio et aI., 1989) , and some data were even incompatible with the first part of the sleep period, and stage 2 was decreased during the total night. In addition, plasma cortisol levels increased earlier than under placebo, and plasma GH levels were reduced in the second part of the night. Thus, only discrete effects of tropisetron upon sleep-endocrine activity were noted, making it unlikely that serotoninergic neurotransmission exerts its well documented effects upon sleep through 5HT3 receptors. [Neuropsychopharmacology 11:101-106, 1994J the view that serotoninergic stimulation produces be havioral sleep accompanied by slow waves in the neo cortex (Robertson et al. 1991) . However, it remained undisputed that serotoninergic neurotransrnission is es sential for sleep regulation in general.
Elucidation of the exact mechanisms involved re quired analysis of the functional role of central 5HT receptors. To date, these SHT receptors have been divided into four classes: 5HTl-like, SHT2, SHT3 (Brad ley et a1. 1986), and SHT4 (Dumuis et al. 1988) . The SHT 1 receptor family can be further subdivided into six subtypes: SHTIA to SHTIF (Frazer et al. 1990 , McAl lister et al. 1992 , Adham et al. 1993 . The few studies conducted on the effects of rather specmc SHT recep tor ligands on the sleep EEG indicate that 5HT2 recep tor antagonists induce slow wave sleep in humans (Id zikowski et al. 1986; Dijk et a1. 1989) and in the rat. The effect of SHT2 receptor antagonists on REM sleep is less clear, as some (Sommerfeldt et al. 1987; Borbely et a1. 1988; Tortella et a1. 1989 ), but not all (Silhol et a1. 1991 ) studies have reported suppression of REM sleep. Only a few ligands from the 5HTI receptor family have been studied. A reduction in REM sleep has been ob-served after 5HT lA receptor agonist treatment of rats with ipsapirone (Tissier et al. 1990 ), or eltoprazine (Quattrochi et al. 1992) .
Among the 5HT receptors, the 5HT3 class is unique because unlike the other 5HT receptors, these recep tors are directly coupled to a cation channel, and their electrophysiological and molecular characterization suggests that the 5HT 3-gated ion channel is most closely related to the nonNMDA/kainate-activated glutamate channel (Hollman et al. 1989; Maricq et al. 1991) .
The 5HT3 receptor class is of interest for future clinical applications because antagonizing this recep tor is known to prevent nausea and vomiting in cancer patients undergoing chemotherapy, radiotherapy, or both, and may also have anxiolytic, antipsychotic, and memory enhancing effects (Cutler 1990) .
Tropisetron ) is a tool to study effects of 5HT3 receptor modulation on central nervous sys tem (CNS) activity. At a cellular level, this compound was characterized as a 5HT3 antagonist (Richardson et al. 1985) . Tropisetron binds to 5HT3 receptors in the human brain (Waeber et al. 1989) . Preclinical experi ments demonstrated the substance to be a CNS active drug. In detail, anxiolytic effects of tropisetron are sug gested from experiments in mice (Onaivi and Martin 1989) and Mongolian gerbils (Cutler 1990) . In rats, the compound was shown to be capable to reduce aversive properties of drug stimuli (Acquas et al. 1990 ). In a re cent clinical trial, an anxiolytic effect of tropisetron was found in patients with generalized anxiety disorder (Lecrubier et al. 1993 ). The present study explores the effects of the 5HT 3 antagonist tropisetron on sleep and sleep-associated secretion of cortisol and growth hor mone (GH) in humans.
MATERIALS AND METHODS

Subjects
Twelve healthy male volunteers (aged 21 to 31 years, mean: 26.8 ± 3.0 SO) participated in the study. None of the subjects had a personal or family history of psy chiatric or neurological illness. All subjects underwent a thorough psychiatric and physical examination, as well as laboratory tests including hematology, clinical chemistry, TRH test, EEG, and ECG prior to the study.
Shift workers and individuals with a history of transmeridian flights during the past six months were excluded from the study. Subjects were rejected if there was a history of abuse of drugs, alcohol, or caffeine, or if there was any drug treatment within the three months prior to the study. No intake of alcohol or coffee (apart from one cup of coffee in the morning) was al lowed during the study period.
All individuals gave written, informed consent af- NEUROPSYCHOPHARMACOLOGY 1994-VOL. 11, NO.2 ter the purpose and protocol of the study had been ex· plained to them. The study was approved by the loc al ethics committee.
Procedure
Each subject spent 11 successive nights in the sleep lab oratory. The fIrst two nights (nights -1 and 0) served as adaptation nights for the experimental conditions. Elec· trodes were applied between 1945 hours and 2015 hours. Lights were switched off at 2300 hours and the subjects were awakened at 0700 hours the following morning. They were not allowed to sleep outside these hours. During nights one to nine, the sleep EEG was recorded between 2300 and 0700 hours using standard methodology (Rechtschaffen and Kales 1968) .
On nights minus one to two, and nights eight and nine, the subjects were given placebo orally at 2200 hours. On nights three to seven, the fIrst four subjects received 5 mg tropisetron and the other eight 25 mg tropisetron orally at 2200 hours.
On days two and seven, an indwelling catheter was inserted into a forearm vein at 2030 hours. The cathe· ter was connected to a plastic tube leading through a soundproof lock into the adjoining laboratory. The cath· eter was kept patent by a continuous 0.9% saline drip containing 200 units of heparine/500 ml solution.
Between 2100 hours and 0700 hours blood samples were taken every 20 min for later analysis of the plasma concentrations of GH and cortisol.
Analysis of sleep EEG and hormone profIles was performed as described in detail elsewhere (Steiger et al. 1987) . The area-under-the-concentration-time-course· curve was computed following the trapezoid rule.
Sleep EEG recordings were scored manually ac· cording to standard guidelines (Rechtschaffen and Kales 1968) If a signifIcant effect was proven, subsequent group by group comparisons were analyzed by the Wilcoxon rank test. To exclude potential effects of cannulation on the sleep EEG (Adam 1982; Jarrett et al. 1984) , nights two and seven were excluded from this analysis. Endocrine variables before and during treatment (nights 2 and 7, respectively) were compared with the Wilcoxon rank test. 7.0 ± 2.4 14.2 ± 3.7 10.1 ± 4.2 p < 0.05 (Pl, P2 < T) REM density 2.4 ± 1.8 1.9 ± 0.9 2.0 ± 1.0 NS 2nd third Time awake (%) 0. 8 ± 1.6 1.2 ± 1.5 0.2 ± 0.3 NS Slow wave sleep (%)
9.2 ± 6.9 8.0 ± 3.5 10.8 ± 6.3 NS REM sleep (%) 28.5 ± 10.5 25.7 ± 4.9 22.5 ± 8.2 NS REM density 2.4 ± 0.7 2.6 ± 1.0 2.3 ± 0.9 NS 3rd third Time awake (%) 5.1 ± 12.0 1.6 ± 0.8 0.2 ± 0.3 NS Slow wave sleep (%)
1.6 ± 2.2 2.0 ± 1.7 1.4 ± 2.6 NS REM sleep (%) 27.4 ± 9.4 29.9 ± 4.5 31.9 ± 4. 9 NS REM density 2.4 ± 0.7 2.6 ± 0.8 2.8 ± 0.9 NS Abbreviations: P1 = Placebo 1; P2 = Placebo 2; ANOYA = analysis of variance; NS = nonsignificant; T = active treatment with 25 mg Tropisetron (day 3-6) Numerical entries in columns two through four are mean ± SO.
RESULTS
Sleep EGG
Effects of 5 mg Tropisetron. None of the conventional sleep variables showed any systematic change under 5 mg tropisetron compared to placebo. (Data not shown.)
Effects of 25 mg Tropisetron. The sleep EEG variables before, during, and after treatment with the substance are given in Table 1 . REM sleep in the fIrst third of the night was slightly, but signifIcantly increased under the drug. There was a slight increase in stage 2 sleep after withdrawal of 25 mg tropisetron. No other statistically signifIcant effects on sleep-EEG variables were noted. We reevaluated our data by visual inspection re garding possible transient effects of the drug and a pos sible compensatory rebound phenomenon after with drawal, however, there were no hints detectable for such phenomena (Figure 1 ). Effects of 25 mg Tropisetron. Table 2 summarizes the endocrine variables before and under active medication. The latency between "lights off" at 2300 hours and the cortisol rise (Steiger et a1. 1987) was shortened under 25 mg tropisetron (p< .05). The GH concentration dur ing the second half of the night was reduced (p < .05). No other signifIcant differences between placebo and 25 mg tropisetron were observed.
Endocrine Variables
Effects of
Side-effects
In general, the substance was well tolerated. Consti pation was reported by eight subjects while taking tropisetron (three subjects on 5 mg and fIve on 25 mg). The effect disappeared after discontinuation of the drug. No clinically signifIcant changes in laboratory values were detected.
DISCUSSION
This study failed to document a profound effect of 5HT3 receptors in regulation of human sleep. In a re cent study (Lecrubier et a1. 1993 ), a statistically sig- Similar to our findings, in a previous study in rats, no major sleep EEG findings by SHT3 receptor antag onists were found (Adrien et al. 1992) . The only changes were that the higher (25 mg) dose of tropisetron slightly reduced stage 2 during the entire night and increased REM sleep during the first third of the night, whereas the amount of REM sleep of the entire night, on aver age, remained stable. The latter finding correlates with the report by Tissier et al. (1990) that showed an increase in REM sleep during the first two hours after adminis tration of the S HT3 antagonist ondansetron in rats.
Furthermore, the effects of SHT3 receptor antago nists on nocturnal secretion of cortisol and GH were not pronounced. Plasma cortisol concentrations began to increase earlier under 2S mg tropisetron than under S mg or placebo. Such a reduced latency of nocturnal cortisol surge is a characteristic phenomenon in depres sion (Steiger et al. 1989) , where altered serotoninergic neurotransmission is subject to etiological and ther apeutic considerations. Plasma GH concentration dur ing the second half of the night was reduced under a dosage of 2S mg tropisetron. It is unclear if this was a direct effect of the drug because the major secretory ac tivity of somatotrophic cells, regularly occurring after sleep onset, remained unaffected by tropisetron.
In contrast to the SHT antagonist used here, other SHT receptor ligands are quite effective modulators of endocrine activity: For example, the SHT lA antagonists ipsapirone, gepirone, and buspirone elevate plasma ACTH and cortisol concentrations (Gilbert et al. 1988; Lesch et al. 1989; Lesch et a1. 1990; Walsh et a1. 1991) whereas the SHT 1 0 receptor sumatriptan fails to affect pituitary-adrenocortical activity, but profoundly stimu lates GH secretion (Rolandi et al. 1992) . The effects of SHT2 receptors in mediating endocrine activity are less documented, and only indirect evidence exists that the activation results in ACTH release (Plotsky et al. 1989) .
All endocrine data were gathered from studies in the waking state. Caution is therefore warranted in any comparisons with our data because the endogenous hormone secretion is different during sleep (Steiger et al. 1987) . Within these limitations, we conclude that the SHT3 receptor antagonist tropisetron has no substan tial effect on physiological sleep-EEG changes and noc turnal secretion of GH and cortisol. These findings need amplification by further analysis of SHT3 receptor selectivity of tropisetron (i.e., binding to SHT3 recep tor subtypes, or SHT4 receptor binding and character ization of the endocrine profile of this compound in the waking state).
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